SAP-001 is a novel, clinical stage (IIb) small molecule designed to address the large and growing unmet medical needs associated with refractory and tophaceous gout, with the potential to eliminate existing tophi, prevent new tophi formation, and reduce the risk of recurrent gout attacks. It has shown the unique ability in clinical studies to decrease and sustain reduced serum uric acid (sUA) levels to < 3 mg/dL at the highest tablet strength for as long as is needed to dissolve tophi, and to provide a chronic maintenance treatment at a lower dose, keeping sUA under the target level of < 6mg/dL for a long period of time. Based on this flexible dosing system in combination with a benign safety profile, we believe that SAP-001 is the First-in-Class to offer a complete solution for gout and hyperuricemia, and has the potential to become the Best-in-Class treatment for refractory and/or tophaceous gout patients and for patients that are not well controlled on allopurinol and/or febuxostat, a sizable market with a revenue potential of over $1 billion in the US alone.

Over time, we believe that SAP-001 has the potential to become the treatment of choice for gout and hyperuricemia.